Ecaterina E Dumbrava, M.D.

Peer-Reviewed Articles

1. Meric-Bernstam F, Johnson AM, Dumbrava EEI, Raghav K, Balaji K, Bhatt M, Murthy RK, Rodon J, Piha-Paul SA. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. Clin Cancer Res 25(7):2033-2041, 2019. e-Pub 2018. PMID: 30442682.
2. Ileana Dumbrava E, Smith V, Alfattal R, El-Naggar AK, Penas-Prado M, Tsimberidou AM. Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment with Ipilimumab and Radiation Therapy. J Immunother 41(7):336-339, 2018. PMID: 29787423.
3. Ileana Dumbrava E, Meric-Bernstam F, Yap TA. Challenges with biomarkers in cancer drug discovery and development. Expert Opin Drug Discov 13(8):685-690, 2018. e-Pub 2018. PMID: 29792354.
4. Dumbrava EI, Ivan D, Subbiah V. Hypopigmented Skin Lesions After Immunotherapy. JAMA Oncol 4(8):1118-1119, 2018. PMID: 29801033.
5. Kurnit K, Dumbrava EI , Litzenburger B, Khotskaya Y, Johnson A, Yap T, Rodon J, Zeng J, Shufean A, Bailey A, Sánchez N, Holla V, Mendelsohn J, Shaw K; Bernstam E, Mills G, Meric-Bernstam F.. Precision oncology decision support: current approaches and strategies for the future. Clinical Cancer Research 24(12):2719-2731, 2018. PMID: 29420224.
6. Dumbrava EEI, Meric-Bernstam F.. Personalized cancer therapy- leveraging a knowledge base for clinical decision-making. Cold Spring Harb Mol Case Study 4(2):1-9, 2018. PMID: 29212833.
7. Ileana-Dumbrava E, Subbiah V. Autoimmune hypophysitis. Lancet Oncol 19(2):e123, 2018. PMID: 29413466.
8. Daniels M, Wathoo C, Brusco L, Lu K, Shaw K, Ileana Dumbrava E, Arun B, Strong L, Litton J, Eterovic AK, Aytac U, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Active Disclosure of Secondary Germline Findings to Deceased Research Participants’ Personal Representatives: Process and Outcomes. JCO Precision Oncology. e-Pub 2017.
9. Hollebecque A, Bahleda R, Faivre L, Adam J, Poinsignon V, Paci A, Gomez-Roca C, Thery JC, Le Deley MC, Varga A, Gazzah A, Ileana E, Gharib M, Angevin E, Malekzadeh K, Massard C, Soria JC, Spano JP. Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours. Eur J Cancer 81:81-89, 2017. e-Pub 2017. PMID: 28618305.
10. Benajiba L, Michot JM, Baldini C, Faivre L, Varga A, Balheda R, Gazzah A, Ileana E, Postel-Vinay S, Massard C, de Botton S, Soria JC, Ribrag V. Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system. Anticancer Drugs 28(5):540-545, 2017. PMID: 28225458.
11. Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, Verlingue L, Ileana E, Rosellini S, Ammari S, Ngo-Camus M, Bahleda R, Gazzah A, Varga A, Postel-Vinay S, Loriot Y, Even C, Breuskin I, Auger N, Job B, De Baere T, Deschamps F, Vielh P, Scoazec JY, Lazar V, Richon C, Ribrag V, Deutsch E, Angevin E, Vassal G, Eggermont A, André F, Soria JC. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discov 7(6):586-595, 2017. e-Pub 2017. PMID: 28365644.
12. Jovelet C, Ileana E, Le Deley MC, Motté N, Rosellini S, Romero A, Lefebvre C, Pedrero M, Pata-Merci N, Droin N, Deloger M, Massard C, Hollebecque A, Ferté C, Boichard A, Postel-Vinay S, Ngo-Camus M, De Baere T, Vielh P, Scoazec JY, Vassal G, Eggermont A, André F, Soria JC, Lacroix L. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial. Clin Cancer Res 22(12):2960-8, 2016. e-Pub 2016. PMID: 26758560.
13. Tacher V, Le Deley MC, Hollebecque A, Deschamps F, Vielh P, Hakime A, Ileana E, Abedi-Ardekani B, Charpy C, Massard C, Rosellini S, Gajda D, Celebic A, Ferté C, Ngo-Camus M, Gouissem S, Koubi-Pick V, Andre F, Vassal G, Deandreis D, Lacroix L, Soria JC, De Baère T. Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01). Eur J Cancer 59:79-89, 2016. e-Pub 2016. PMID: 27017289.
14. Postel-Vinay S, Boursin Y, Massard C, Hollebecque A, Ileana E, Chiron M, Jung J, Lee JS, Balogh Z, Adam J, Vielh P, Angevin E, Lacroix L, Soria JC. Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?. Ann Oncol 27(2):344-52, 2016. e-Pub 2015. PMID: 26598538.
15. Antoun S, Bayar A, Ileana E, Laplanche A, Fizazi K, di Palma M, Escudier B, Albiges L, Massard C, Loriot Y. High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting. Eur J Cancer 51(17):2570-7, 2015. e-Pub 2015. PMID: 26278649.
16. Kossai M, Duchemann B, Boutros C, Caramella C, Hollebecque A, Angevin E, Gazzah A, Bahleda R, Ileana E, Massard C, Vielh P, Soria JC, Besse B. Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy. Lung Cancer 89(3):306-10, 2015. e-Pub 2015. PMID: 26160757.
17. Loriot Y, Eymard JC, Patrikidou A, Ileana E, Massard C, Albiges L, Di Palma M, Escudier B, Fizazi K. Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer. Eur J Cancer 51(14):1946-52, 2015. e-Pub 2015. PMID: 26208462.
18. Ileana EE, Wistuba II, Izzo JG. From Uniplex to Multiplex Molecular Profiling in Advanced Non-Small Cell Lung Carcinoma. Cancer J 21(5):413-24, 2015. PMID: 26389767.
19. Touat M, Ileana E, Postel-Vinay S, André F, Soria JC. Targeting FGFR Signaling in Cancer. Clin Cancer Res 21(12):2684-94, 2015. PMID: 26078430.
20. Patrikidou A, Loriot Y, Eymard JC, Albiges L, Massard C, Ileana E, Di Palma M, Escudier B, Fizazi K. Who dies from prostate cancer?. Prostate Cancer Prostatic Dis 17(4):348-52, 2014. e-Pub 2014. PMID: 25311767.
21. Champiat S, Ileana E, Giaccone G, Besse B, Mountzios G, Eggermont A, Soria JC. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. J Thorac Oncol 9(2):144-53, 2014. PMID: 24419410.
22. Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, Albiges L, Attard G, Fizazi K, De Bono JS, Massard C. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 24(7):1807-12, 2013. e-Pub 2013. PMID: 23576708.
23. Ileana E, Champiat S, Soria JC. Immune-checkpoints: the new anti-cancer immunotherapies. Bull Cancer 100(6):601-10, 2013. PMID: 23735730.
24. Ileana E, Greillier L, Moutardier V, Barlesi F. Surgical resection of liver non-small cell lung cancer metastasis: a dual weapon?. Lung Cancer 70(2):221-2, 2010. e-Pub 2010. PMID: 20828859.
25. F, Legodec J, Maldonado Ileana E, Greillier L, Dutau H, Astoul Ph.. Pathologie pleurale. Revue des Maladies Respiratoires 2(Suppl 1):106-120, 2010.

Abstracts

1. McKean M, Dumbrava EE|| b, Hamid O, Merriam P, Mettu NB, Call JA, Kapoun AM, Lucas J, Seetharam M, Vaishampayan UN, Veroha SJ, Krishnan S, George AJ. Safety and efficacy of etigilimab in combination with nivolumab in select recurrent/advanced solid tumors. J Clin Oncol: Proceedings of the 2022 ASCO Annual Meeting 40(suppl 16), 2022.
2. Dumbrava EE, Shapiro G, Bendell JC, Yap TA, Jeselsohn R, Lepley DM, Hurley S, Lin KK, Liao M, Habeck J, Enke A, Hamilton EP. Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors. J Clin Oncol 39(suppl 15), 2021.
3. Pairawan SS, Yuca E, Evans K, Annis A, Narasimhan N, Sutton D, Carvajal LA, Ren J-G, Santiago S, Guerlavais V, Akcakanat A, Tapia C, Ileana Dumbrava E, Aivado M, Meric-Bernstam F. The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, enhances antitumor efficacy of paclitaxel and Nab-paclitaxel in TP53 wild-type MCF-7 breast cancer models. Cancer Research 79(Suppl 4):pp. P6-20-11, 2019.
4. Owusu-Brackett N, Zhao M, Akcakanat A, Evans KW, Yuca E, Tapia C, Ileana Dumbrava E, Janku F, Meric-Bernstam F.. Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss. 2018 San Antonio Breast Cancer Symposium Volume 79(4 Suppl):pp. P6-21-04, 2019.
5. Ileana Dumbrava EE, Huang HJ, Stuckett A, Madwani K, Adat A, Hong DS, Piha-Paul SA, Subbiah V, Karp DD, Fu S, Naing A, Tsimberidou AM, Moulder S, Koeing K, Barcenas CH, Kee B, Fogelman D, Kopetz S, Meric-Bernstam F, Janku F.. PIK3CA mutations in plasma cell-free DNA predict survival and treatment outcomes in patients with advanced cancers. Targeting PI3K/mTOR Signaling, 2018.
6. Owusu-Brackett, Evans KW, Akcakanat, Yuca E, Ileana Dumbrava E, Janku F, Meric-Bernstam F.. TAK288 enhances anti tumor activity of eribulin in triple negative breast cancer. Oncotarget, 2018.
7. Ileana Dumbrava E, Balaji K, Raghav K, Javle M, Blum-Murphy M, Sajan B, Kopetz S, Broaddus R, Routbort M, Pant S, Tsimberidou A, Subbiah V, Hong D, Rodon J, Shaw K, Piha-Paul S, Meric-Bernstam F.. Targeting HER2 (ERBB2) amplification identified by next-generation sequencing (NGS) in patients with advanced or metastatic solid tumors. Mol Cancer Ther 17(1 Suppl):#A167, 2018.
8. Ileana Dumbrava E, Brusco L, Daniels MS, Wathoo C, Shaw K, Lu K, Zheng X, Strong LC, Litton J, Arun B, Eterovic A, Piha-Paul S, Subbiah V, Hong DS, Woodman S, Mendelsohn J, Yap T, Mills CB, Chen K, Meric-Bernstam F. Pathogenic variants in DNA damage response (DDR) genes in patients with advanced solid tumors. J Clin Oncol 35(15 Suppl):#11567, 2017.
9. Ileana Dumbrava E, Brusco L, Daniels MS, Wathoo C, Shaw K, Lu K, Zheng X, Strong LC, Litton J, Arun B, Eterovic A, M Routbort, Piha-Paul S, Subbiah V, Hong DS, Kopetz S, Mendelsohn J, Yap T, Mills CB, Chen K, Meric-Bernstam F. Prevalence of incidental germline pathogenic (PV) and likely pathogenic (LPV) variants in hereditary cancer-related genes identified in matched tumor/normal sequencing of advanced solid tumors. J Clin Oncol 35(15 Suppl):#1524, 2017.
10. Shien K, Ruder D, Ileana E, Papadimitrakopoulou VA. Frampton GM, Behrens C, Kalhor N, Lee JJ, Tang X, Herbst RS, Wistuba II, Izzo JG. Detection of a novel ALK fusion variant in lung adenocarcinoma using a comprehensive genomic analysis. Cancer Research 76(suppl 14):pp. 1144, 2016.
11. Ileana E, Jovelet C, Le Deley MC, Massard C, Motté N, Hollebecque A, Boichard A, Ferté C, Postel-Vinay S, Rosellini S, Ngo-Camus M, De Baere T, Vielh P, Richon C, Laporte M, Gouissem S, Loriot Y, Bahleda R, Gazzah A, Varga A, Vassal G, Eggermont A, André F, Soria JC, Lacroix L.. Circulating cell-free tumor DNA (cfDNA) analysis of 50-genes by next-generation sequencing (NGS) in the prospective MOSCATO trial. Cancer Res 75(15 Suppl):#2401, 2015.
12. Ferté C, Massard C, Ileana E, Hollebecque A, Lacroix L, Ammari S, Ngo-Camus M, Bahleda R, Gazzah A, Varga A, Postel-Vinay S, Loriot Y, Auger N, Koubi-Pick V, Job B, De Baere T, Deschamps F, Vielh P, Lazar V, Le Deley MC, Richon C, Ribrag V, Deutsch E, Angevin E, Vassal G, Eggermont A, André F, Soria JC. Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial; Interim analysis of 420 patients. Cancer Res 74(19 Suppl):#CT240, 2014.
13. Ileana E, Antoun S, Albiges L, Massard C, Di Palma M, Escudier B, Fizazi K, Loriot Y. Effects of abiraterone acetate and enzalutamide on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol: Proceedings of the ASCO Annual Meeting 31(Suppl 15):#5088, 2013.
14. Bianchini D, Loriot Y, Ileana E, Sandhu S, Pezaro C, Albiges L, Attard G, Fizazi K, de Bono JS, Massard C.. Abiraterone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and MDV3100: a multicentre study. Annals of Oncology 23(Suppl 9):#924P, 2012.
15. Ileana E, Maldonado F, Astoul P.. Where did my central line go? The pinch-off syndrome. Cancer Imaging 10(Suppl):#200, 2010.
16. Ileana E, Diaconu B, Tantau M, Laugier R. Efficacy of endoscopic treatment in chronic pancreatitis assessed by Izbicki Score. Pancreatology 9:#P-103, 2009.